VRTX
Closed
Vertex Pharmaceuticals Inc
468.
-1 (-0.21%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 468.57
Day's Range: 463.04 - 471.89
Send
sign up or login to leave a comment!
When Written:
324.83
Vertex Pharmaceuticals Inc. is a biotechnology company that focuses on the development of innovative medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex is known for its work in the field of cystic fibrosis (CF), a genetic disease that affects the lungs and digestive system.
Vertex's flagship CF drug is called Kalydeco, which was approved by the FDA in 2012. Kalydeco is designed to treat CF patients with specific genetic mutations. Since then, Vertex has developed several other CF drugs, including Orkambi, Symdeko, and Trikafta, which have been approved by the FDA and are used to treat a wider range of CF patients.
In addition to CF, Vertex is also developing treatments for other serious diseases, including alpha-1 antitrypsin deficiency, sickle cell disease, and beta thalassemia. The company has a strong research and development pipeline, with a focus on developing precision medicines that target specific genetic mutations.
Vertex has a global presence, with offices and research facilities in the United States, Canada, Europe, and Australia. The company has received numerous awards and recognition for its work in biotechnology, including being named one of the world's most innovative companies by Forbes magazine.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Vertex's flagship CF drug is called Kalydeco, which was approved by the FDA in 2012. Kalydeco is designed to treat CF patients with specific genetic mutations. Since then, Vertex has developed several other CF drugs, including Orkambi, Symdeko, and Trikafta, which have been approved by the FDA and are used to treat a wider range of CF patients.
In addition to CF, Vertex is also developing treatments for other serious diseases, including alpha-1 antitrypsin deficiency, sickle cell disease, and beta thalassemia. The company has a strong research and development pipeline, with a focus on developing precision medicines that target specific genetic mutations.
Vertex has a global presence, with offices and research facilities in the United States, Canada, Europe, and Australia. The company has received numerous awards and recognition for its work in biotechnology, including being named one of the world's most innovative companies by Forbes magazine.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!